Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, GROW Funds. This analysis is provided for institutional research purposes only and is not investment advice.
"GROW Funds capped a stellar 2024 with 26-31% net returns, utilizing active trading to lock in massive gains in top-performing industrial and tech holdings while initiating fresh positions in high-upside biotech."
GROW Funds LLC reported robust performance for full-year 2024, with net returns of +26% to 31%, comfortably outperforming the Russell 2000 Growth and Russell 2500 Growth benchmarks. The firm is actively managing portfolio risk by trimming highly successful long-term compounders (AGX, GHM, ZETA) and recycling capital into high-conviction new additions like Axsome Therapeutics (AXSM). Despite mid-quarter macroeconomic concerns, including interest rate fluctuations and a major short attack on holding Zeta Global, the managers maintain a strong, bullish outlook for 2025, driven by structural tailwinds in AI infrastructure, defense pipelines, and anticipated domestic regulatory and tax relief.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon